Linde T, Wahlberg J, Wikström B, Danielson B G
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Clin Nephrol. 1992 May;37(5):260-3.
The introduction of treatment with recombinant human erythropoietin (rhEPO) has raised the possibility of deleterious effects on early kidney graft function. Due to renal anemia, the great majority of patients waiting for kidney transplantation until now have had a low hematocrit. It has been suggested that a low hematocrit is beneficial for early kidney graft function by protecting the transplanted kidney from so-called reperfusion damage, which results in delayed onset of renal function. We have retrospectively examined the early function of 26 kidney grafts transplanted to uremic patients with rhEPO corrected anemia. Compared with a randomized control group no significant differences were seen in the rate of immediate onset of graft function, graft survival or serum levels of creatinine one year after transplantation. We conclude that the reversing of anemia by rhEPO in recipients of cadaver kidneys does not impair early graft function.
重组人促红细胞生成素（rhEPO）治疗方法的引入增加了对早期肾移植功能产生有害影响的可能性。由于肾性贫血，到目前为止，绝大多数等待肾移植的患者血细胞比容都很低。有人认为，低血细胞比容通过保护移植肾免受所谓的再灌注损伤，对早期肾移植功能有益，而再灌注损伤会导致肾功能延迟出现。我们回顾性地研究了26例移植给rhEPO纠正贫血的尿毒症患者的肾移植早期功能。与随机对照组相比，移植后即刻移植肾功能的发生率、移植肾存活率或肌酐血清水平在一年后没有显著差异。我们得出结论，rhEPO纠正尸体肾受者的贫血不会损害早期移植肾功能。
